Frank E, Kupfer D J, Buhari A, McEachran A B, Grochocinski V J
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pennsylvania 15213.
J Affect Disord. 1992 Sep;26(1):65-72. doi: 10.1016/0165-0327(92)90036-6.
The recently completed long-term maintenance trial of full-dose imipramine for recurrent unipolar disorder provided an opportunity to examine the extent to which such doses (200-300 mg daily) are associated with persistent and adverse side effects, particularly weight change. In 115 patients we monitored weight change during the three-year maintenance treatment phase to the point of trial completion, recurrence or termination. No differences were noted between individuals receiving active medication (average gain of 5.8 lbs. during an average treatment period of 725 days) versus those randomized to the 'no-drug' cells (average gain of 2.8 lbs. during an average treatment period of 422 days). Numerous other factors such as body mass index, previous weight gain and gender did not play a differential role in establishing why some individuals gained weight during long-term treatment of depression regardless of specific treatment.
最近完成的关于复发性单相抑郁症的全剂量丙咪嗪长期维持试验，提供了一个机会来检验这种剂量（每日200 - 300毫克）与持续性不良副作用，特别是体重变化之间的关联程度。在115名患者中，我们在为期三年的维持治疗阶段监测体重变化，直至试验完成、复发或终止。接受活性药物治疗的个体（在平均725天的治疗期内平均体重增加5.8磅）与随机分配到“无药物”组的个体（在平均422天的治疗期内平均体重增加2.8磅）之间未发现差异。许多其他因素，如体重指数、既往体重增加情况和性别，在解释为何有些个体在长期抑郁症治疗期间体重增加（无论具体治疗方式如何）方面并未发挥差异作用。
